Risperdal (risperidone) and Abilify (aripiprazole) are both second-generation antipsychotics, but they work on dopamine in opposite ways. Risperidone blocks dopamine D2 receptors outright. Aripiprazole is a partial agonist: it turns dopamine signalling down where there is too much and slightly up where there is too little. That one difference explains most of what separates them in practice. Risperidone tends to raise prolactin and cause more weight gain, and in large analyses it controls psychotic symptoms slightly better. Aripiprazole is usually gentler on weight and prolactin, but it is more likely to cause restlessness (akathisia), and it carries an FDA warning about impulse-control problems.
This guide compares the two drugs on approved uses, dosing, side effects, use in children with autism, drug interactions, long-acting injections, and switching, using the FDA prescribing information and the main comparative studies.
This is general information, not medical advice. Both are prescription medicines. Never start, stop, switch or combine antipsychotics without the prescriber who manages your treatment.
Risperdal vs Abilify at a glance
| Risperdal (risperidone) | Abilify (aripiprazole) | |
|---|---|---|
| How it acts on dopamine | D2 antagonist (blocks the receptor), plus strong serotonin 5-HT2A blockade | D2 partial agonist, plus 5-HT1A partial agonism and 5-HT2A blockade |
| FDA-approved uses | Schizophrenia, bipolar I mania (alone or with lithium or valproate), irritability with autism | Schizophrenia, bipolar I (acute and maintenance), add-on for depression, irritability with autism, Tourette’s disorder |
| Youngest approved age | 5 years (autism irritability) | 6 years (autism irritability and Tourette’s) |
| Usual adult dose, schizophrenia | Start 2 mg/day, target 4 to 8 mg/day | Start 10 to 15 mg/day, range 10 to 30 mg/day |
| Half-life | About 20 hours for the active drug plus its metabolite | About 75 hours (94 hours for its active metabolite) |
| Prolactin | Often raised, sometimes markedly | Usually unchanged or lowered |
| Weight gain | Moderate | Lower in adults; less clear-cut in children |
| Restlessness (akathisia) | Possible, more at higher doses | One of its most common side effects |
| Special warnings | Dementia-related psychosis (boxed) | Dementia-related psychosis and suicidal thoughts with antidepressant use (boxed); impulse-control problems |
| Long-acting injections | Risperdal Consta, Perseris, Uzedy, Rykindo | Abilify Maintena, Abilify Asimtufii, Aristada |
| Generic available | Yes | Yes |
How they work, and why it matters
Psychosis and mania are linked to too much dopamine activity in certain brain pathways. Both drugs reduce that activity, but by different routes.
Risperidone sits on the D2 receptor and blocks it. It also blocks serotonin 5-HT2A receptors strongly, which is what makes it an “atypical” antipsychotic and lowers movement side effects compared with older drugs such as haloperidol. Because it blocks dopamine everywhere it reaches, it also blocks dopamine’s job of keeping prolactin in check. That is why raised prolactin is one of risperidone’s signature effects.
Aripiprazole is a partial agonist. It binds D2 receptors tightly but switches them on only part of the way. Where dopamine is high, it lowers the overall signal. Where dopamine is low, it provides a little stimulation. In practice this means less effect on prolactin (levels often fall), and a lower risk of the stiffness and tremor that full blockers cause. The trade-off is that partial stimulation can leave people feeling restless or driven, which shows up as akathisia, insomnia, and in rare cases impulse-control problems.
What each drug is approved for
| Condition | Risperdal | Abilify |
|---|---|---|
| Schizophrenia | Adults and ages 13 to 17 | Adults and ages 13 to 17 |
| Bipolar I mania or mixed episodes | Adults and ages 10 to 17 (alone); adults with lithium or valproate | Adults and ages 10 to 17, alone or with lithium or valproate |
| Bipolar I maintenance | Long-acting injection (Risperdal Consta) only | Yes (oral and long-acting injections) |
| Depression (add-on to an antidepressant) | No | Adults |
| Irritability with autism | Ages 5 to 17 | Ages 6 to 17 |
| Tourette’s disorder | No | Ages 6 to 18 |
Abilify has the broader label. The two indications Risperdal lacks, add-on treatment for depression and Tourette’s, are often why a prescriber picks aripiprazole. Doctors do sometimes prescribe either drug outside its label, but the approved uses tell you where the strongest trial evidence sits.
Which works better?
There is no single winner. The largest comparison of antipsychotics for adults with schizophrenia, a 2019 network meta-analysis of 32 drugs published in The Lancet (Huhn and colleagues), ranked risperidone among the more effective drugs for overall symptom reduction. Aripiprazole sat in the middle of the pack for efficacy. Aripiprazole scored better on several tolerability measures. It had the lowest significant increase in the need for anti-Parkinson medication (a stand-in for movement side effects) of any drug that showed one. And unlike risperidone, it did not raise prolactin.
The differences in efficacy are modest at the group level and smaller than the differences between individuals. Many people respond well to one and poorly to the other. That’s why prescribers usually choose based on side-effect risk, other conditions, and past response rather than on rankings.
Risperdal vs Abilify for autism
These are the only two medicines FDA-approved for irritability associated with autism. That covers aggression, deliberate self-injury, temper tantrums and quickly changing moods. Neither treats the core features of autism, such as social communication differences.
- Head-to-head trial: a two-month double-blind trial in 59 children and adolescents (Ghanizadeh and colleagues, 2014) found both drugs lowered irritability scores. Neither did significantly better, and side-effect rates were similar. Mean doses were 5.5 mg/day of aripiprazole and 1.12 mg/day of risperidone.
- Network meta-analysis: a 2019 analysis of eight trials and 878 children (Fallah and colleagues) found risperidone and aripiprazole reduced irritability by almost the same amount compared with placebo. The authors called them the two best options, with comparable efficacy and safety.
- Side effects in children: both drugs can cause weight gain and sleepiness in children, and the weight gap between them is smaller than in adults. Risperidone raises prolactin. Aripiprazole tends to lower it.
Risperidone is approved from age 5 and has the longer track record, with more placebo-controlled trials behind it. Aripiprazole is approved from age 6 and is often chosen when prolactin or weight is a particular worry. For a child who doesn’t respond to one, trying the other is a common next step.
Dosing compared
| Use | Risperdal (starting dose → usual range) | Abilify (starting dose → usual range) |
|---|---|---|
| Schizophrenia, adults | 2 mg/day → 4 to 8 mg/day (up to 16 mg) | 10 to 15 mg/day → 10 to 30 mg/day |
| Schizophrenia, ages 13 to 17 | 0.5 mg/day → 3 mg/day target (1 to 6 mg) | 2 mg/day → 10 mg/day target (up to 30 mg) |
| Bipolar mania, adults | 2 to 3 mg/day → 1 to 6 mg/day | 15 mg/day (alone) or 10 to 15 mg/day (add-on) → up to 30 mg/day |
| Depression add-on, adults | Not approved | 2 to 5 mg/day → 2 to 15 mg/day |
| Autism irritability | 0.25 mg/day (under 20 kg) or 0.5 mg/day → 0.5 to 3 mg/day | 2 mg/day → 5 to 15 mg/day |
| Tourette’s | Not approved | 2 mg/day → 5 to 10 mg/day (under 50 kg) or 10 to 20 mg/day (50 kg and over) |
The milligram numbers are not comparable. 2 mg of risperidone is not “weaker” than 10 mg of aripiprazole. They are different molecules with different potency. Both come as tablets, orally disintegrating tablets and an oral liquid, which helps for children or anyone who struggles with pills.
Half-life matters day to day. Risperidone and its active metabolite clear in about a day. Aripiprazole’s half-life is about 75 hours, and its metabolite’s about 94. Aripiprazole takes about two weeks to reach a steady level, so dose changes take a while to show their full effect, good or bad. A missed dose of aripiprazole matters less. Side effects can also take longer to fade after stopping.
Side effects compared

Weight gain and metabolic effects
Both labels warn about weight gain, raised blood sugar and changed cholesterol, and both call for monitoring. In adults, risperidone usually causes more weight gain than aripiprazole. In children the picture is less tidy. Aripiprazole still causes weight gain compared with placebo, and some studies show the gap closing over several months. Whichever drug is used, weight, waist size, blood sugar and lipids should be checked at the start, after about three months, and then regularly.
Prolactin
This is the clearest difference. Risperidone raises prolactin in many patients. High prolactin can cause missed or stopped periods, breast enlargement or milk discharge (in any sex), lower sex drive, erectile problems and, over years, lower bone density. Aripiprazole usually leaves prolactin normal or lowers it. That’s why it is often the switch of choice when prolactin side effects appear.
Movement side effects and restlessness
Risperidone causes more dose-related stiffness, tremor and slowed movement (parkinsonism), especially above about 6 mg a day. Aripiprazole causes less of that but more akathisia: an inner restlessness, an inability to sit still, pacing. Akathisia is easy to mistake for worsening anxiety or agitation, so report it to the prescriber, who can often fix it by adjusting the dose. Both drugs carry the class warning for tardive dyskinesia, involuntary movements that can become permanent with long-term use.
Sedation
Risperidone is more likely to cause sleepiness, which some people find useful at bedtime. Aripiprazole is more often activating. Insomnia, nausea and headache are common early on, and it is usually taken in the morning.
Impulse-control problems (Abilify)
In 2016 the FDA added a warning that aripiprazole can cause compulsive urges to gamble, binge eat, shop or have sex, in people with no history of these behaviours. The urges usually stopped when the dose was lowered or the drug was stopped. Because people often don’t link these urges to a medicine, family members are asked to watch for them too.
Boxed warnings and serious risks
- Both: older adults with dementia-related psychosis have a higher risk of death when treated with antipsychotics. Neither drug is approved for this use.
- Abilify only: because it is approved as an add-on for depression, it carries the antidepressant boxed warning about suicidal thoughts and behaviour in children, teens and young adults.
- Both: neuroleptic malignant syndrome (rare but serious: high fever, rigid muscles, confusion), low white blood cell counts, low blood pressure on standing, seizures, difficulty swallowing, and trouble regulating body temperature.
Drug interactions
Both drugs are broken down by liver enzymes. Medicines that block or speed up those enzymes change the dose you actually get.
- Aripiprazole uses CYP2D6 and CYP3A4. The label tells prescribers to halve the dose with strong CYP2D6 inhibitors (such as fluoxetine, paroxetine or bupropion) or strong CYP3A4 inhibitors (such as clarithromycin or ketoconazole). With both kinds, or in people who are poor CYP2D6 metabolizers, the dose is cut to a quarter. Strong inducers such as carbamazepine or rifampin call for doubling the dose.
- Risperidone uses mainly CYP2D6. Fluoxetine and paroxetine raise its levels, and carbamazepine lowers them, so doses may need adjusting when these are started or stopped.
- Both: alcohol, opioids, benzodiazepines and sleep medicines add to sedation and dizziness. Blood pressure medicines add to the drop in blood pressure on standing.
The fluoxetine and paroxetine interactions matter most, because antidepressants are often prescribed alongside these drugs. You can compare SSRIs, including their interaction risk, in our SSRI comparison tool. For drinking, see our alcohol and medication interaction checker.
Long-acting injections
For people who find daily pills hard to keep up with, both drugs come as long-acting injections given by a clinician:
- Risperidone: Risperdal Consta (into the muscle every 2 weeks), Rykindo (every 2 weeks), Perseris (under the skin monthly) and Uzedy (under the skin every 1 or 2 months).
- Aripiprazole: Abilify Maintena (monthly), Abilify Asimtufii (every 2 months) and Aristada (every 4 to 8 weeks depending on dose).
Tolerability on the oral form is usually established first. Each product has its own start-up schedule, and some need oral overlap for a few weeks.
Switching between Risperdal and Abilify
There is no fixed conversion ratio between the two (people search for a “Risperdal to Abilify conversion”, but none exists). Prescribers usually cross-taper: they start the new drug at a low dose and raise it while lowering the old one over one to several weeks.
- Risperidone to aripiprazole: aripiprazole’s long half-life means it builds up slowly. Stopping risperidone too fast can cause a gap in coverage, or “rebound” sleeplessness and agitation as risperidone’s sedation wears off.
- Aripiprazole to risperidone: aripiprazole lingers for a week or more after the last dose, so its effects overlap with the new drug for a while.
- Prolactin: after switching from risperidone to aripiprazole, prolactin-related symptoms often ease over weeks.
Can Risperdal and Abilify be taken together?
Sometimes, under specialist care. The most common reason is prolactin. When risperidone works well but raises prolactin, some prescribers add a low dose of aripiprazole to bring prolactin down rather than give up a drug that is working. Combining antipsychotics for symptom control is less well supported and adds side-effect burden, so guidelines generally prefer one antipsychotic at an adequate dose before combining. Overlapping the two during a switch also counts as taking them together for a short time.
Pregnancy and breastfeeding
Both labels warn that newborns exposed to antipsychotics in the third trimester can have temporary movement symptoms or withdrawal symptoms (agitation, feeding difficulty, breathing problems). Neither drug is clearly linked to major birth defects in the available data, and there are national pregnancy registries for both. Untreated psychosis or mania also carries real risks in pregnancy, so the decision is a balance that should be made with the prescriber, ideally before conception. Both drugs pass into breast milk in small amounts. Risperidone’s effect on prolactin, and aripiprazole’s tendency to lower it (which can reduce milk supply), are both relevant if you plan to breastfeed.
Who each one might suit
| Situation | Often favours | Why |
|---|---|---|
| Prolactin side effects, or plans for pregnancy | Abilify | Usually doesn’t raise prolactin |
| Weight or diabetes is a major concern | Abilify | Lower metabolic risk in adults |
| Add-on for depression, or Tourette’s | Abilify | Only Abilify is approved for these |
| Agitation, insomnia, or past akathisia on aripiprazole | Risperdal | More calming; less akathisia |
| History of gambling or impulse-control problems | Risperdal | Avoids aripiprazole’s impulse-control warning |
| Child under 6 with autism-related irritability | Risperdal | Approved from age 5 |
| Need for the fastest dose adjustments | Risperdal | Shorter half-life, steady state in days |
These are tendencies, not rules. Past response to either drug, family history of response, cost and coverage, and other medicines all feed into the choice.
Practical tips if you take either drug
- Ask for baseline weight, blood sugar and cholesterol checks, and repeat them about three months in.
- Report restlessness, stiffness, tremor or unusual mouth and tongue movements early, rather than waiting for the next appointment.
- On risperidone, tell the prescriber about period changes, breast changes or sexual side effects. These are treatable, often by switching.
- On aripiprazole, tell family members about the impulse-control warning so they can flag new gambling, spending or eating patterns.
- Stand up slowly at first, especially in the early weeks or after a dose increase.
- Don’t stop suddenly. Relapse risk is real, and stopping should be planned with the prescriber.
For another common comparison, see Abilify vs Seroquel. If negative symptoms of schizophrenia are the main problem, our guide to Vraylar and negative symptoms covers a newer option.
Frequently asked questions
Is Abilify better than Risperdal?
Not overall. In large analyses of schizophrenia trials, risperidone controls symptoms slightly better on average, while aripiprazole causes less weight gain and prolactin elevation. For autism-related irritability, head-to-head and pooled data show the two work about equally. The better drug is the one that controls your symptoms with side effects you can live with.
Which causes more weight gain, Risperdal or Abilify?
In adults, risperidone usually causes more. In children both can cause meaningful weight gain, and the gap is smaller. Monitoring is recommended with either.
Can you take Risperdal and Abilify together?
Only under a prescriber’s direction. The best-established reason is adding low-dose aripiprazole to bring down prolactin raised by risperidone. They also overlap briefly during a switch.
Which is better for autism, Risperdal or Abilify?
Both are FDA-approved for irritability associated with autism, and studies show they work about equally. Risperidone is approved from age 5, aripiprazole from age 6. Aripiprazole is often preferred when prolactin is a concern, and risperidone when sleep or agitation is a bigger problem.
How do you convert a Risperdal dose to Abilify?
There is no standard conversion. Prescribers usually start aripiprazole at a low dose and adjust it to response while tapering risperidone over one to several weeks.
References
- Risperdal (risperidone) prescribing information. Janssen. DailyMed.
- Abilify (aripiprazole) prescribing information. Otsuka. DailyMed.
- FDA Drug Safety Communication: FDA warns about new impulse-control problems associated with mental health drug aripiprazole (Abilify, Abilify Maintena, Aristada). May 3, 2016.
- MHRA Drug Safety Update: Aripiprazole (Abilify and generic brands): risk of pathological gambling. December 2023.
- Huhn M, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;394:939-951.
- Ghanizadeh A, Sahraeizadeh A, Berk M. A head-to-head comparison of aripiprazole and risperidone for safety and treating autistic disorders, a randomized double blind clinical trial. Child Psychiatry Hum Dev. 2014;45:185-192.
- Fallah MS, et al. Atypical antipsychotics for irritability in pediatric autism: a systematic review and network meta-analysis. J Child Adolesc Psychopharmacol. 2019.
- Risperidone. StatPearls. NCBI Bookshelf.
- Aripiprazole. StatPearls. NCBI Bookshelf.
About this article
Written by the Health Linear Editorial Team from primary sources such as FDA prescribing information, DailyMed, NIH and peer-reviewed studies, which are linked in the article. Last updated October 28, 2026.
Read our editorial process and medical disclaimer. Spotted an error? Tell us and we will correct it.